{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:01:25Z","timestamp":1776834085110,"version":"3.51.2"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04812-9","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:16:13Z","timestamp":1773479773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic profiling enables personalized strategies to overcome drug resistance in multiple myeloma"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5711-9051","authenticated-orcid":false,"given":"Fengbo","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2451-9216","authenticated-orcid":false,"given":"Azin","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"12","key":"4812_CR1","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.18632\/oncotarget.1497","volume":"4","author":"J Abdi","year":"2013","unstructured":"Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4(12):2186\u2013207.","journal-title":"Oncotarget"},{"issue":"2","key":"4812_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/jclinpath-2015-203414","volume":"69","author":"N Nikesitch","year":"2016","unstructured":"Nikesitch N, Ling SC. Molecular mechanisms in multiple myeloma drug resistance. J Clin Pathol. 2016;69(2):97\u2013101.","journal-title":"J Clin Pathol"},{"key":"4812_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, et al. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"4812_CR4","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"P Bhatt","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R. Relapsed\/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322\u201347.","journal-title":"Curr Oncol"},{"issue":"2","key":"4812_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","volume":"33","author":"AK Dutta","year":"2019","unstructured":"Dutta AK, et al. Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 2019;33(2):457\u201368.","journal-title":"Leukemia"},{"issue":"19","key":"4812_CR6","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-24-0210","volume":"30","author":"D Kazandjian","year":"2024","unstructured":"Kazandjian D, et al. Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Clin Cancer Res. 2024;30(19):4482\u201390.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4812_CR7","first-page":"87","volume":"1","author":"J Nass","year":"2018","unstructured":"Nass J, Efferth T. Drug targets and resistance mechanisms in multiple myeloma. Cancer Drug Resist. 2018;1(2):87\u2013117.","journal-title":"Cancer Drug Resist"},{"key":"4812_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/164_2017_10","volume":"249","author":"A Papadas","year":"2018","unstructured":"Papadas A, Asimakopoulos F. Mechanisms of Resistance in Multiple Myeloma. Handb Exp Pharmacol. 2018;249:251\u201388.","journal-title":"Handb Exp Pharmacol"},{"key":"4812_CR9","doi-asserted-by":"crossref","unstructured":"Pinto V et al. Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers (Basel), 2020. 12(2).","DOI":"10.3390\/cancers12020407"},{"issue":"9","key":"4812_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5306\/wjco.v10.i9.303","volume":"10","author":"J Zhou","year":"2019","unstructured":"Zhou J, Chng W-J. Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. World J Clin Oncol. 2019;10(9):303.","journal-title":"World J Clin Oncol"},{"issue":"3","key":"4812_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12185-016-2048-5","volume":"104","author":"Y Furukawa","year":"2016","unstructured":"Furukawa Y, Kikuchi J. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. Int J Hematol. 2016;104(3):281\u201392.","journal-title":"Int J Hematol"},{"issue":"4","key":"4812_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","volume":"111","author":"Y Furukawa","year":"2020","unstructured":"Furukawa Y, Kikuchi J. Molecular basis of clonal evolution in multiple myeloma. Int J Hematol. 2020;111(4):496\u2013511.","journal-title":"Int J Hematol"},{"issue":"4","key":"4812_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/10428194.2012.728597","volume":"54","author":"YX Zhu","year":"2013","unstructured":"Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683\u20137.","journal-title":"Leuk Lymphoma"},{"key":"4812_CR14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2147\/OTT.S130742","volume":"10","author":"Z Zheng","year":"2017","unstructured":"Zheng Z, et al. Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network. Onco Targets Ther. 2017;10:1327\u201334.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"4812_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova L, et al. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014;18(6):947\u201361.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"4812_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/ijo.2016.3516","volume":"49","author":"SR Krishnan","year":"2016","unstructured":"Krishnan SR, et al. Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). Int J Oncol. 2016;49(1):33\u201350.","journal-title":"Int J Oncol"},{"issue":"3","key":"4812_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12185-016-2040-0","volume":"104","author":"S Iida","year":"2016","unstructured":"Iida S. Mechanisms of action and resistance for multiple myeloma novel drug treatments. Int J Hematol. 2016;104(3):271\u20132.","journal-title":"Int J Hematol"},{"issue":"2","key":"4812_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/10428194.2012.706287","volume":"54","author":"G Bianchi","year":"2013","unstructured":"Bianchi G, Ghobrial IM. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leuk Lymphoma. 2013;54(2):229\u201341.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"4812_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1634\/theoncologist.2019-0356","volume":"25","author":"MC Da Vi\u00e0","year":"2020","unstructured":"Da Vi\u00e0 MC, et al. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. Oncologist. 2020;25(2):112\u20138.","journal-title":"Oncologist"},{"issue":"1","key":"4812_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22\u201332.","journal-title":"Leukemia"},{"issue":"5","key":"4812_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3109\/08923973.2012.658921","volume":"34","author":"R Castelli","year":"2012","unstructured":"Castelli R, et al. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacol Immunotoxicol. 2012;34(5):740\u201353.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"5","key":"4812_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","volume":"33","author":"H van Andel","year":"2019","unstructured":"van Andel H, et al. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019;33(5):1063\u201375.","journal-title":"Leukemia"},{"issue":"2","key":"4812_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7150\/thno.28374","volume":"9","author":"V Vikova","year":"2019","unstructured":"Vikova V, et al. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. Theranostics. 2019;9(2):540\u201353.","journal-title":"Theranostics"},{"issue":"5","key":"4812_CR24","first-page":"1336","volume":"22","author":"YY Lu","year":"2014","unstructured":"Lu YY, et al. [Molecular mechanism of Doxorubicin resistance in multiple myeloma cell line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22(5):1336\u201340.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"38","key":"4812_CR25","doi-asserted-by":"publisher","first-page":"40496","DOI":"10.18632\/oncotarget.5800","volume":"6","author":"R Franqui-Machin","year":"2015","unstructured":"Franqui-Machin R, et al. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget. 2015;6(38):40496\u2013506.","journal-title":"Oncotarget"},{"issue":"3","key":"4812_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41375-020-0989-4","volume":"35","author":"K Allmeroth","year":"2021","unstructured":"Allmeroth K, et al. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia. 2021;35(3):887\u201392.","journal-title":"Leukemia"},{"issue":"5","key":"4812_CR27","first-page":"1074","volume":"110","author":"PJ Teoh","year":"2025","unstructured":"Teoh PJ, et al. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica. 2025;110(5):1074\u201391.","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"4812_CR28","first-page":"3","volume":"25","author":"KC Anderson","year":"2011","unstructured":"Anderson KC. Multiple myeloma: a clinical overview. Oncol (Williston Park). 2011;25(Suppl 2):3\u20139.","journal-title":"Oncol (Williston Park)"},{"key":"4812_CR29","doi-asserted-by":"crossref","unstructured":"Bobin A et al. Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020. Cancers (Basel), 2020. 12(10).","DOI":"10.3390\/cancers12102885"},{"issue":"3","key":"4812_CR30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/cancers17030354","volume":"17","author":"F Fazio","year":"2025","unstructured":"Fazio F, et al. Long-Term Survival with Multiple Myeloma: An Italian Experience. Cancers. 2025;17(3):354.","journal-title":"Cancers"},{"issue":"8","key":"4812_CR31","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"key":"4812_CR32","doi-asserted-by":"publisher","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando AG, et al. Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. Front Oncol. 2022;12:973836.","journal-title":"Front Oncol"},{"issue":"1\u20132","key":"4812_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000318880","volume":"125","author":"A Kumar","year":"2011","unstructured":"Kumar A, Galeb S, Djulbegovic B. Treatment of patients with multiple myeloma: an overview of systematic reviews. Acta Haematol. 2011;125(1\u20132):8\u201322.","journal-title":"Acta Haematol"},{"key":"4812_CR34","doi-asserted-by":"crossref","unstructured":"Abd A, B. and, Mohammed M. Multiple Myeloma, the Plasma Cell Cancer: An Overview. Med J Babylon, 2020. 17.","DOI":"10.4103\/MJBL.MJBL_20_20"},{"issue":"1","key":"4812_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12254-018-0383-3","volume":"11","author":"E Willenbacher","year":"2018","unstructured":"Willenbacher E, Balog A, Willenbacher W. Short overview on the current standard of treatment in newly diagnosed multiple myeloma. Memo. 2018;11(1):59\u201364.","journal-title":"Memo"},{"issue":"10","key":"4812_CR36","first-page":"684","volume":"42","author":"R Eslick","year":"2013","unstructured":"Eslick R, Talaulikar D. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician. 2013;42(10):684\u20138.","journal-title":"Aust Fam Physician"},{"issue":"8","key":"4812_CR37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/17474086.2019.1634541","volume":"12","author":"M Martino","year":"2019","unstructured":"Martino M, et al. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. Expert Rev Hematol. 2019;12(8):665\u201384.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"4812_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-023-00806-w","volume":"13","author":"N Leung","year":"2023","unstructured":"Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023;13(1):46.","journal-title":"Blood Cancer J"},{"key":"4812_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/IJNRD.S280179","volume":"15","author":"P Men\u00e8","year":"2022","unstructured":"Men\u00e8 P, et al. Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges. Int J Nephrol Renovasc Dis. 2022;15:173\u201383.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"8","key":"4812_CR40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5694\/mja2.50129","volume":"210","author":"DE Joshua","year":"2019","unstructured":"Joshua DE, et al. Biology and therapy of multiple myeloma. Med J Aust. 2019;210(8):375\u201380.","journal-title":"Med J Aust"},{"issue":"1","key":"4812_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1586\/17474086.2014.870030","volume":"7","author":"RA Kyle","year":"2014","unstructured":"Kyle RA, Rajkumar SV. An overview of the progress in the treatment of multiple myeloma. Expert Rev Hematol. 2014;7(1):5\u20137.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"4812_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/2040620715572295","volume":"6","author":"C Phipps","year":"2015","unstructured":"Phipps C, et al. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015;6(3):120\u20137.","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"4812_CR43","first-page":"e3148","volume":"10","author":"A Rafae","year":"2018","unstructured":"Rafae A, et al. An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring. Cureus. 2018;10(8):e3148.","journal-title":"Cureus"},{"issue":"17","key":"4812_CR44","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1080\/14656566.2017.1404575","volume":"18","author":"DC Ziogas","year":"2017","unstructured":"Ziogas DC, et al. An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin Pharmacother. 2017;18(17):1883\u201397.","journal-title":"Expert Opin Pharmacother"},{"key":"4812_CR45","doi-asserted-by":"crossref","unstructured":"Devarakonda S et al. Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. J Clin Med, 2020. 9(11).","DOI":"10.3390\/jcm9113626"},{"issue":"6","key":"4812_CR46","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00228-017-2227-1","volume":"73","author":"BE Oortgiesen","year":"2017","unstructured":"Oortgiesen BE, et al. The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study. Eur J Clin Pharmacol. 2017;73(6):771\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"4812_CR47","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.2147\/DDDT.S267404","volume":"15","author":"M Offidani","year":"2021","unstructured":"Offidani M, et al. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Des Devel Ther. 2021;15:2401\u201315.","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"4812_CR48","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","volume":"33","author":"AH Bazarbachi","year":"2019","unstructured":"Bazarbachi AH, et al. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343\u201357.","journal-title":"Leukemia"},{"issue":"3","key":"4812_CR49","doi-asserted-by":"publisher","first-page":"9054","DOI":"10.4081\/hr.2020.9054","volume":"12","author":"N Bolli","year":"2020","unstructured":"Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep. 2020;12(3):9054.","journal-title":"Hematol Rep"},{"issue":"32","key":"4812_CR50","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.21.01045","volume":"39","author":"P Sonneveld","year":"2021","unstructured":"Sonneveld P, et al. Consolidation and maintenance in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39(32):3613\u201322.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4812_CR51","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37(7):589\u201397.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4812_CR52","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1590\u20139.","journal-title":"J Clin Oncol"},{"issue":"22","key":"4812_CR53","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315.","journal-title":"N Engl J Med"},{"key":"4812_CR54","doi-asserted-by":"crossref","unstructured":"Committee, E.H.A.G., et al., Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up <\u2009sup>\u2020. Annals of Oncology, 2021. 32(3): pp. 309\u2013322.","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"4812_CR55","doi-asserted-by":"crossref","unstructured":"San Miguel Jes\u00fas F et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med 359(9): pp. 906\u201317.","DOI":"10.1056\/NEJMoa0801479"},{"key":"4812_CR56","doi-asserted-by":"publisher","first-page":"844779","DOI":"10.3389\/fonc.2022.844779","volume":"12","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Bertuglia G, Oliva S. Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results. Front Oncol. 2022;12:844779.","journal-title":"Front Oncol"},{"issue":"7","key":"4812_CR57","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.3390\/curroncol29070355","volume":"29","author":"ME Stalker","year":"2022","unstructured":"Stalker ME, Mark TM. Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies. Curr Oncol. 2022;29(7):4464\u201377.","journal-title":"Curr Oncol"},{"key":"4812_CR58","doi-asserted-by":"publisher","first-page":"1370854","DOI":"10.3389\/fonc.2024.1370854","volume":"14","author":"F Riccardi","year":"2024","unstructured":"Riccardi F, et al. Targeted therapy for multiple myeloma: an overview on CD138-based strategies. Front Oncol. 2024;14:1370854.","journal-title":"Front Oncol"},{"issue":"4","key":"4812_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","volume":"35","author":"M Nikolaou","year":"2018","unstructured":"Nikolaou M, et al. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35(4):309\u201318.","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"4812_CR60","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","volume":"25","author":"AJ Sabnis","year":"2019","unstructured":"Sabnis AJ, Bivona TG. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019;25(3):185\u201397.","journal-title":"Trends Mol Med"},{"issue":"7782","key":"4812_CR61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299\u2013309.","journal-title":"Nature"},{"issue":"2","key":"4812_CR62","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","volume":"121","author":"A Chaidos","year":"2013","unstructured":"Chaidos A, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. 2013;121(2):318\u201328.","journal-title":"Blood"},{"issue":"6","key":"4812_CR63","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","volume":"41","author":"M Dang","year":"2023","unstructured":"Dang M, et al. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023;41(6):1032\u2013e10474.","journal-title":"Cancer Cell"},{"issue":"7","key":"4812_CR64","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","volume":"36","author":"K Misund","year":"2022","unstructured":"Misund K, et al. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia. 2022;36(7):1887\u201397.","journal-title":"Leukemia"},{"key":"4812_CR65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/978-3-030-62080-6_19","volume-title":"Principles of Personalized Oncology, in Textbook of Personalized Medicine","author":"KK Jain","year":"2021","unstructured":"Jain KK. Principles of Personalized Oncology, in Textbook of Personalized Medicine. Cham: Springer International Publishing; 2021. pp. 403\u201378. K.K. Jain, Editor."},{"issue":"17","key":"4812_CR66","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1073\/pnas.1418631112","volume":"112","author":"A Belkadi","year":"2015","unstructured":"Belkadi A, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci U S A. 2015;112(17):5473\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4812_CR67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41698-024-00788-3","volume":"9","author":"IA Kerle","year":"2025","unstructured":"Kerle IA, et al. Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncology. npj Precision Oncol. 2025;9(1):9.","journal-title":"npj Precision Oncol"},{"key":"4812_CR68","doi-asserted-by":"publisher","first-page":"15086","DOI":"10.1038\/ncomms15086","volume":"8","author":"O Kis","year":"2017","unstructured":"Kis O, et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nat Commun. 2017;8:15086.","journal-title":"Nat Commun"},{"issue":"W1","key":"4812_CR69","doi-asserted-by":"publisher","first-page":"W520","DOI":"10.1093\/nar\/gkad408","volume":"51","author":"F-C Qian","year":"2023","unstructured":"Qian F-C, et al. SEanalysis 2.0: a comprehensive super-enhancer regulatory network analysis tool for human and mouse. Nucleic Acids Res. 2023;51(W1):W520\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"4812_CR70","first-page":"313","volume":"142","author":"MK Samur","year":"2023","unstructured":"Samur MK, Szalat R, Munshi NC. Single-cell profiling in multiple myeloma: insights, problems, and promises. Blood. 2023;142(4):313\u201324.","journal-title":"Blood"},{"key":"4812_CR71","doi-asserted-by":"publisher","first-page":"p6782046","DOI":"10.1155\/2020\/6782046","volume":"20201","author":"B He","year":"2020","unstructured":"He B, et al. Gene coexpression network and module analysis across 52 human tissues. Biomed Res Int. 2020;20201:p6782046.","journal-title":"Biomed Res Int"},{"issue":"1","key":"4812_CR72","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41467-022-28266-z","volume":"13","author":"M Merz","year":"2022","unstructured":"Merz M, et al. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nat Commun. 2022;13(1):807.","journal-title":"Nat Commun"},{"key":"4812_CR73","doi-asserted-by":"crossref","unstructured":"Sudupe L et al. Bone marrow spatial transcriptomics reveals a myeloma cell architecture with dysfunctional T-Cell distribution, neutrophil traps, and inflammatory signaling. bioRxiv, 2024: p. 2024.07. 03.601833.","DOI":"10.1101\/2024.07.03.601833"},{"issue":"1","key":"4812_CR74","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/hematology.2021000304","volume":"2021","author":"A Visram","year":"2021","unstructured":"Visram A, Cook J, Warsame R. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. Hematology. 2021;2021(1):673\u201381.","journal-title":"Hematology"},{"issue":"12","key":"4812_CR75","doi-asserted-by":"publisher","first-page":"105894","DOI":"10.1016\/j.esmoop.2025.105894","volume":"10","author":"E Krieghoff-Henning","year":"2025","unstructured":"Krieghoff-Henning E, et al. Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board. ESMO open. 2025;10(12):105894.","journal-title":"ESMO open"},{"key":"4812_CR76","doi-asserted-by":"crossref","unstructured":"Liu Y, Elmas A, Huang K-l. Mutation impact on mRNA versus protein expression across human cancers. bioRxiv, 2023.","DOI":"10.1101\/2023.11.13.566942"},{"key":"4812_CR77","doi-asserted-by":"publisher","first-page":"0859","DOI":"10.34133\/research.0859","volume":"8","author":"Y Qu","year":"2025","unstructured":"Qu Y, et al. Proteogenomic Analysis Identifies Clinically Relevant Subgroups of Collecting Duct Carcinoma. Research. 2025;8:0859.","journal-title":"Research"},{"issue":"10","key":"4812_CR78","first-page":"1122","volume":"20","author":"K Schwarze","year":"2018","unstructured":"Schwarze K, et al. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Sci. 2018;20(10):1122\u201330.","journal-title":"Genet Sci"},{"issue":"11","key":"4812_CR79","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.3390\/ijms19113503","volume":"19","author":"C-H Yen","year":"2018","unstructured":"Yen C-H, Hsiao H-H. NRF2 is one of the players involved in bone marrow mediated drug resistance in multiple myeloma. Int J Mol Sci. 2018;19(11):3503.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4812_CR80","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/10428194.2014.907890","volume":"56","author":"J Abraham","year":"2015","unstructured":"Abraham J, Salama NN, Azab AK. The role of P-glycoprotein in drug resistance in multiple myeloma. Leuk Lymphoma. 2015;56(1):26\u201333.","journal-title":"Leuk Lymphoma"},{"key":"4812_CR81","doi-asserted-by":"crossref","unstructured":"Heming CP et al. P-glycoprotein and cancer: what do we currently know? Heliyon, 2022. 8(10).","DOI":"10.1016\/j.heliyon.2022.e11171"},{"key":"4812_CR82","doi-asserted-by":"crossref","unstructured":"Zhang S et al. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy. J Inflamm Res, 2025: pp. 4335\u201357.","DOI":"10.2147\/JIR.S499403"},{"key":"4812_CR83","doi-asserted-by":"crossref","unstructured":"Kyrtsonis M-C et al. Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity. Application Clin Genet, 2010: pp. 41\u201351.","DOI":"10.2147\/TACG.S7456"},{"issue":"1","key":"4812_CR84","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1186\/s12885-022-09775-y","volume":"22","author":"A Salimi","year":"2022","unstructured":"Salimi A, et al. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK. BMC Cancer. 2022;22(1):735.","journal-title":"BMC Cancer"},{"issue":"21","key":"4812_CR85","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.3390\/cancers14215340","volume":"14","author":"G Wang","year":"2022","unstructured":"Wang G, et al. Looking into endoplasmic reticulum stress: the key to drug-resistance of multiple myeloma? Cancers. 2022;14(21):5340.","journal-title":"Cancers"},{"key":"4812_CR86","doi-asserted-by":"publisher","first-page":"889954","DOI":"10.3389\/fimmu.2022.889954","volume":"13","author":"KR Hamedi","year":"2022","unstructured":"Hamedi KR, et al. Autophagy and the bone marrow microenvironment: a review of protective factors in the development and maintenance of multiple myeloma. Front Immunol. 2022;13:889954.","journal-title":"Front Immunol"},{"issue":"10","key":"4812_CR87","doi-asserted-by":"publisher","first-page":"e25820","DOI":"10.1371\/journal.pone.0025820","volume":"6","author":"A-S Michallet","year":"2011","unstructured":"Michallet A-S, et al. Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells. PLoS ONE. 2011;6(10):e25820.","journal-title":"PLoS ONE"},{"issue":"11","key":"4812_CR88","doi-asserted-by":"publisher","first-page":"M110","DOI":"10.1074\/mcp.M110.005520","volume":"10","author":"Y Xiang","year":"2011","unstructured":"Xiang Y, et al. Monitoring a nuclear factor-\u03baB signature of drug resistance in multiple myeloma. Mol Cell Proteom. 2011;10(11):M110.","journal-title":"Mol Cell Proteom"},{"key":"4812_CR89","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"D Niewerth","year":"2015","unstructured":"Niewerth D, et al. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updates. 2015;18:18\u201335.","journal-title":"Drug Resist Updates"},{"issue":"1","key":"4812_CR90","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-017-0492-1","volume":"10","author":"N Rastgoo","year":"2017","unstructured":"Rastgoo N, et al. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. J Hematol Oncol. 2017;10(1):121.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"4812_CR91","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3390\/ijms19051512","volume":"19","author":"S Manni","year":"2018","unstructured":"Manni S, et al. Old and young actors playing novel roles in the drama of multiple myeloma bone marrow microenvironment dependent drug resistance. Int J Mol Sci. 2018;19(5):1512.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4812_CR92","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1186\/s12885-019-6446-y","volume":"19","author":"Y Huang","year":"2019","unstructured":"Huang Y, et al. Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM). BMC Cancer. 2019;19(1):1269.","journal-title":"BMC Cancer"},{"issue":"6","key":"4812_CR93","first-page":"1666","volume":"1865","author":"D Bruennert","year":"2019","unstructured":"Bruennert D, et al. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. Biochim et Biophys acta (BBA)-molecular basis disease. 2019;1865(6):1666\u201376.","journal-title":"Biochim et Biophys acta (BBA)-molecular basis disease"},{"issue":"1","key":"4812_CR94","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"Y Tai","year":"2014","unstructured":"Tai Y, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155\u201365.","journal-title":"Leukemia"},{"issue":"7","key":"4812_CR95","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2174\/156800912802429337","volume":"12","author":"P Neri","year":"2012","unstructured":"Neri P, Bahlis NJ. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets. 2012;12(7):776\u201396.","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"4812_CR96","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/abbs\/gmt142","volume":"46","author":"X Chang","year":"2014","unstructured":"Chang X, et al. Mechanism of immunomodulatory drugs\u2019 action in the treatment of multiple myeloma. Acta Biochim Biophys Sin. 2014;46(3):240\u201353.","journal-title":"Acta Biochim Biophys Sin"},{"key":"4812_CR97","doi-asserted-by":"publisher","first-page":"1020011","DOI":"10.3389\/fonc.2022.1020011","volume":"12","author":"M Mejia Saldarriaga","year":"2022","unstructured":"Mejia Saldarriaga M, et al. Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Front Oncol. 2022;12:1020011.","journal-title":"Front Oncol"},{"issue":"1","key":"4812_CR98","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1038\/s41467-024-47793-5","volume":"15","author":"M Binder","year":"2024","unstructured":"Binder M, et al. Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes. Nat Commun. 2024;15(1):4139.","journal-title":"Nat Commun"},{"issue":"1","key":"4812_CR99","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/mutage\/gez019","volume":"35","author":"AR Kaplan","year":"2020","unstructured":"Kaplan AR, Glazer PM. Impact of hypoxia on DNA repair and genome integrity. Mutagenesis. 2020;35(1):61\u20138.","journal-title":"Mutagenesis"},{"issue":"16","key":"4812_CR100","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.3390\/cancers13164069","volume":"13","author":"J Sch\u00fctt","year":"2021","unstructured":"Sch\u00fctt J, et al. Investigating the interplay between myeloma cells and bone marrow stromal cells in the development of drug resistance: dissecting the role of epigenetic modifications. Cancers. 2021;13(16):4069.","journal-title":"Cancers"},{"issue":"1","key":"4812_CR101","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/ajco.13459","volume":"17","author":"Y Bai","year":"2021","unstructured":"Bai Y, Su X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia\u2010Pacific J Clin Oncol. 2021;17(1):29\u201335.","journal-title":"Asia\u2010Pacific J Clin Oncol"},{"issue":"7","key":"4812_CR102","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/cancers13071686","volume":"13","author":"LN Davis","year":"2021","unstructured":"Davis LN, Sherbenou DW. Emerging therapeutic strategies to overcome drug resistance in multiple myeloma. Cancers. 2021;13(7):1686.","journal-title":"Cancers"},{"issue":"7","key":"4812_CR103","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.3390\/ijms24076019","volume":"24","author":"H Bashiri","year":"2023","unstructured":"Bashiri H, Tabatabaeian H. Autophagy: a potential therapeutic target to tackle drug resistance in multiple myeloma. Int J Mol Sci. 2023;24(7):6019.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4812_CR104","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","volume":"13","author":"JN Vo","year":"2022","unstructured":"Vo JN, et al. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022;13(1):3750.","journal-title":"Nat Commun"},{"key":"4812_CR105","doi-asserted-by":"publisher","first-page":"1243997","DOI":"10.3389\/fimmu.2023.1243997","volume":"14","author":"S Forster","year":"2023","unstructured":"Forster S, Radpour R, Ochsenbein AF. Molecular and immunological mechanisms of clonal evolution in multiple myeloma. Front Immunol. 2023;14:1243997.","journal-title":"Front Immunol"},{"issue":"6","key":"4812_CR106","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/cancers13061353","volume":"13","author":"A Diaz-Tejedor","year":"2021","unstructured":"Diaz-Tejedor A, et al. Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression. Cancers. 2021;13(6):1353.","journal-title":"Cancers"},{"issue":"2","key":"4812_CR107","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","volume":"64","author":"AS Rosenberg","year":"2023","unstructured":"Rosenberg AS. From mechanism to resistance\u2013changes in the use of dexamethasone in the treatment of multiple myeloma. Leuk Lymphoma. 2023;64(2):283\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"4812_CR108","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3390\/jpm11111185","volume":"11","author":"M Costacurta","year":"2021","unstructured":"Costacurta M, et al. Molecular mechanisms of cereblon-interacting small molecules in multiple myeloma therapy. J Personalized Med. 2021;11(11):1185.","journal-title":"J Personalized Med"},{"key":"4812_CR109","doi-asserted-by":"crossref","unstructured":"Innao V et al. Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma. Cells, 2021. 10(2).","DOI":"10.3390\/cells10020439"},{"key":"4812_CR110","doi-asserted-by":"crossref","unstructured":"Fontana F, Anselmi M, Limonta P. Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression. Cancers (Basel), 2022. 14(7).","DOI":"10.3390\/cancers14071614"},{"issue":"5","key":"4812_CR111","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2141.2010.08533.x","volume":"152","author":"SA Hunsucker","year":"2011","unstructured":"Hunsucker SA, et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011;152(5):579\u201392.","journal-title":"Br J Haematol"},{"issue":"1","key":"4812_CR112","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ajh.23868","volume":"90","author":"RZ Orlowski","year":"2015","unstructured":"Orlowski RZ, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015;90(1):42\u20139.","journal-title":"Am J Hematol"},{"issue":"183","key":"4812_CR113","doi-asserted-by":"publisher","first-page":"721","DOI":"10.24976\/Discov.Med.202436183.68","volume":"36","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. EZH2 Promotes Multiple Myeloma Progression via STAT3 Pathway Activation. Discov Med. 2024;36(183):721\u20139.","journal-title":"Discov Med"},{"issue":"17","key":"4812_CR114","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","volume":"119","author":"GL Uy","year":"2012","unstructured":"Uy GL, et al. A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119(17):3917\u201324.","journal-title":"Blood"},{"issue":"2","key":"4812_CR115","doi-asserted-by":"publisher","first-page":"pIjh39","DOI":"10.2217\/ijh-2021-0017","volume":"11","author":"M Bou Zerdan","year":"2022","unstructured":"Bou Zerdan M, et al. Adhesion molecules in multiple myeloma oncogenesis and targeted therapy. Int J Hematol Oncol. 2022;11(2):pIjh39.","journal-title":"Int J Hematol Oncol"},{"issue":"4","key":"4812_CR116","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2967\/jnumed.115.164624","volume":"57","author":"D Soodgupta","year":"2016","unstructured":"Soodgupta D, et al. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. J Nucl Med. 2016;57(4):640\u20135.","journal-title":"J Nucl Med"},{"issue":"1","key":"4812_CR117","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4812_CR118","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41389-022-00380-z","volume":"11","author":"C Giallongo","year":"2022","unstructured":"Giallongo C, et al. CXCL12\/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis. 2022;11(1):6.","journal-title":"Oncogenesis"},{"issue":"23","key":"4812_CR119","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood.2021014749","volume":"140","author":"E Menu","year":"2022","unstructured":"Menu E, Vanderkerken K. Exosomes in multiple myeloma: from bench to bedside. Blood. 2022;140(23):2429\u201342.","journal-title":"Blood"},{"key":"4812_CR120","doi-asserted-by":"publisher","first-page":"1379822","DOI":"10.3389\/fmolb.2024.1379822","volume":"11","author":"B Ren","year":"2024","unstructured":"Ren B, et al. Exosomes: a significant medium for regulating drug resistance through cargo delivery. Front Mol Biosci. 2024;11:1379822.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"4812_CR121","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","volume":"124","author":"J Wang","year":"2014","unstructured":"Wang J, et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124(4):555\u201366.","journal-title":"Blood"},{"issue":"1","key":"4812_CR122","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/0008-5472.CAN-23-0189","volume":"84","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. Hypoxic Bone Marrow Stromal Cells Secrete miR-140-5p and miR-28-3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma. Cancer Res. 2024;84(1):39\u201355.","journal-title":"Cancer Res"},{"key":"4812_CR123","doi-asserted-by":"publisher","first-page":"1155621","DOI":"10.3389\/fonc.2023.1155621","volume":"13","author":"M Matamala Montoya","year":"2023","unstructured":"Matamala Montoya M, et al. Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment. Front Oncol. 2023;13:1155621.","journal-title":"Front Oncol"},{"key":"4812_CR124","doi-asserted-by":"crossref","unstructured":"Melaccio A et al. Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance. J Clin Med, 2022. 11(21).","DOI":"10.3390\/jcm11216491"},{"issue":"1","key":"4812_CR125","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","volume":"15","author":"M Swamydas","year":"2022","unstructured":"Swamydas M, et al. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol. 2022;15(1):17.","journal-title":"J Hematol Oncol"},{"key":"4812_CR126","doi-asserted-by":"crossref","unstructured":"Al-Odat OS et al. Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma. Int J Mol Sci, 2022. 24(1).","DOI":"10.3390\/ijms24010644"},{"issue":"1","key":"4812_CR127","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-022-01683-w","volume":"22","author":"SR Krishnan","year":"2023","unstructured":"Krishnan SR, Bebawy M. Circulating biosignatures in multiple myeloma and their role in multidrug resistance. Mol Cancer. 2023;22(1):79.","journal-title":"Mol Cancer"},{"key":"4812_CR128","doi-asserted-by":"crossref","unstructured":"Botta C et al. Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities. Cancers (Basel), 2021. 13(13).","DOI":"10.3390\/cancers13133213"},{"issue":"3","key":"4812_CR129","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27(3):491\u2013503.","journal-title":"Nat Med"},{"issue":"14","key":"4812_CR130","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood.2022017789","volume":"141","author":"N Giesen","year":"2023","unstructured":"Giesen N, et al. A phase 2 clinical trial of combined BRAF\/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood. 2023;141(14):1685\u201390.","journal-title":"Blood"},{"key":"4812_CR131","doi-asserted-by":"crossref","unstructured":"Szymczyk J et al. FGF\/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance. Cancers (Basel), 2021. 13(22).","DOI":"10.3390\/cancers13225796"},{"issue":"24","key":"4812_CR132","doi-asserted-by":"publisher","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","volume":"17","author":"KD Boyd","year":"2011","unstructured":"Boyd KD, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17(24):7776\u201384.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4812_CR133","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2013.088211","volume":"99","author":"A Gang","year":"2014","unstructured":"Gang A, et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014;99(2):353\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"4812_CR134","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-024-00985-0","volume":"14","author":"K Neupane","year":"2024","unstructured":"Neupane K, et al. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J. 2024;14(1):20.","journal-title":"Blood Cancer J"},{"issue":"3","key":"4812_CR135","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ijc.34243","volume":"152","author":"WK Hofmann","year":"2023","unstructured":"Hofmann WK, Trumpp A, M\u00fcller-Tidow C. Therapy resistance mechanisms in hematological malignancies. Int J Cancer. 2023;152(3):340\u20137.","journal-title":"Int J Cancer"},{"key":"4812_CR136","doi-asserted-by":"publisher","first-page":"684561","DOI":"10.3389\/fonc.2021.684561","volume":"11","author":"A Romano","year":"2021","unstructured":"Romano A, et al. Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. Front Oncol. 2021;11:684561.","journal-title":"Front Oncol"},{"key":"4812_CR137","doi-asserted-by":"publisher","first-page":"891652","DOI":"10.3389\/fonc.2022.891652","volume":"12","author":"TB Emran","year":"2022","unstructured":"Emran TB, et al. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front Oncol. 2022;12:891652.","journal-title":"Front Oncol"},{"key":"4812_CR138","doi-asserted-by":"crossref","unstructured":"Soliman AM, Das S, Teoh SL. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis. Int J Mol Sci, 2021. 22(14).","DOI":"10.3390\/ijms22147470"},{"issue":"4","key":"4812_CR139","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","volume":"2","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2021;2(4):302\u201318.","journal-title":"Blood Cancer Discov"},{"issue":"19","key":"4812_CR140","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood.2023019758","volume":"142","author":"AM Poos","year":"2023","unstructured":"Poos AM, et al. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis. Blood. 2023;142(19):1633\u201346.","journal-title":"Blood"},{"issue":"3","key":"4812_CR141","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.3324\/haematol.2018.212308","volume":"105","author":"EM Algar\u00edn","year":"2020","unstructured":"Algar\u00edn EM, et al. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Haematologica. 2020;105(3):e116\u201320.","journal-title":"Haematologica"},{"issue":"21","key":"4812_CR142","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","volume":"30","author":"P Desai","year":"2024","unstructured":"Desai P, et al. A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed\/Refractory Hematologic Malignancies. Clin Cancer Res. 2024;30(21):4844\u201355.","journal-title":"Clin Cancer Res"},{"key":"4812_CR143","doi-asserted-by":"crossref","unstructured":"Kozalak G et al. Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies. Pharmaceuticals (Basel), 2023. 16(1).","DOI":"10.3390\/ph16010111"},{"issue":"8","key":"4812_CR144","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3324\/haematol.2021.279360","volume":"107","author":"N Giesen","year":"2022","unstructured":"Giesen N, et al. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica. 2022;107(8):1891\u2013901.","journal-title":"Haematologica"},{"key":"4812_CR145","doi-asserted-by":"crossref","unstructured":"Faruq O et al. Targeting an MDM2\/MYC Axis to Overcome Drug Resistance in Multiple Myeloma. Cancers (Basel), 2022. 14(6).","DOI":"10.3390\/cancers14061592"},{"issue":"22","key":"4812_CR146","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1182\/blood.2024028272","volume":"145","author":"KM Kort\u00fcm","year":"2025","unstructured":"Kort\u00fcm KM, Einsele H. Guidance on the interpretation of CRBN mutations in myeloma. Blood. 2025;145(22):2542.","journal-title":"Blood"},{"key":"4812_CR147","doi-asserted-by":"publisher","first-page":"p1943","DOI":"10.1182\/blood-2023-190247","volume":"142","author":"F Garbicz","year":"2023","unstructured":"Garbicz F, et al. Transcriptomic Features Influencing Anti-Myeloma Drug Resistance in Human Multiple Myeloma Cell Lines. Blood. 2023;142:p1943.","journal-title":"Blood"},{"key":"4812_CR148","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1017\/erm.2021.2","volume":"23","author":"M Khanna","year":"2021","unstructured":"Khanna M, et al. Targeting unfolded protein response: a new horizon for disease control. Expert Rev Mol Med. 2021;23:e1.","journal-title":"Expert Rev Mol Med"},{"issue":"10","key":"4812_CR149","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1038\/s41375-021-01373-4","volume":"35","author":"JR Jones","year":"2021","unstructured":"Jones JR, et al. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. Leukemia. 2021;35(10):3017\u201320.","journal-title":"Leukemia"},{"issue":"9","key":"4812_CR150","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood.2020008346","volume":"137","author":"J Corre","year":"2021","unstructured":"Corre J, et al. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood. 2021;137(9):1192\u20135.","journal-title":"Blood"},{"issue":"3","key":"4812_CR151","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-019-0191-y","volume":"9","author":"A Lakshman","year":"2019","unstructured":"Lakshman A, et al. Natural history of multiple myeloma with de novo del(17p). Blood Cancer J. 2019;9(3):32.","journal-title":"Blood Cancer J"},{"issue":"8","key":"4812_CR152","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","volume":"3","author":"M Andrulis","year":"2013","unstructured":"Andrulis M, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3(8):862\u20139.","journal-title":"Cancer Discov"},{"issue":"2","key":"4812_CR153","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.2020007081","volume":"137","author":"S Gooding","year":"2021","unstructured":"Gooding S, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137(2):232\u20137.","journal-title":"Blood"},{"issue":"8","key":"4812_CR154","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41576-021-00338-8","volume":"22","author":"D Chakravarty","year":"2021","unstructured":"Chakravarty D, Solit DB. Clinical cancer genomic profiling. Nat Rev Genet. 2021;22(8):483\u2013501.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"4812_CR155","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3892\/ol.2024.14681","volume":"28","author":"Q Ge","year":"2024","unstructured":"Ge Q, et al. Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review). Oncol Lett. 2024;28(5):548.","journal-title":"Oncol Lett"},{"key":"4812_CR156","doi-asserted-by":"publisher","first-page":"1381212","DOI":"10.3389\/fimmu.2024.1381212","volume":"15","author":"L Li","year":"2024","unstructured":"Li L, et al. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis. Front Immunol. 2024;15:1381212.","journal-title":"Front Immunol"},{"issue":"1","key":"4812_CR157","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1038\/s41467-024-52980-5","volume":"15","author":"A Ianevski","year":"2024","unstructured":"Ianevski A, et al. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones. Nat Commun. 2024;15(1):8579.","journal-title":"Nat Commun"},{"key":"4812_CR158","doi-asserted-by":"publisher","first-page":"706030","DOI":"10.3389\/fonc.2021.706030","volume":"11","author":"G Zhao","year":"2021","unstructured":"Zhao G, et al. Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism. Front Oncol. 2021;11:706030.","journal-title":"Front Oncol"},{"key":"4812_CR159","doi-asserted-by":"crossref","unstructured":"Liu YP et al. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020), 2021. 2(3): pp. 315\u2013340.","DOI":"10.1002\/mco2.55"},{"issue":"10","key":"4812_CR160","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1111\/cas.15087","volume":"112","author":"S Ikeda","year":"2021","unstructured":"Ikeda S, Tagawa H. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma. Cancer Sci. 2021;112(10):3995\u20134004.","journal-title":"Cancer Sci"},{"issue":"1","key":"4812_CR161","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, et al. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1):96.","journal-title":"Mol Cancer"},{"key":"4812_CR162","doi-asserted-by":"crossref","unstructured":"Choi CY et al. Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells. Nutrients, 2022. 14(3).","DOI":"10.3390\/nu14030699"},{"key":"4812_CR163","doi-asserted-by":"publisher","first-page":"3426407","DOI":"10.1155\/2022\/3426407","volume":"2022","author":"S Lu","year":"2022","unstructured":"Lu S, et al. Managing Cancer Drug Resistance from the Perspective of Inflammation. J Oncol. 2022;2022:3426407.","journal-title":"J Oncol"},{"key":"4812_CR164","doi-asserted-by":"crossref","unstructured":"Das S et al. Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment. Int J Mol Sci, 2022. 23(3).","DOI":"10.3390\/ijms23031649"},{"issue":"1","key":"4812_CR165","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","volume":"6","author":"J Kang","year":"2021","unstructured":"Kang J, et al. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther. 2021;6(1):323.","journal-title":"Signal Transduct Target Ther"},{"key":"4812_CR166","doi-asserted-by":"publisher","first-page":"1224125","DOI":"10.3389\/fonc.2023.1224125","volume":"13","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang C, Bao N. Molecular mechanism of palmitic acid and its derivatives in tumor progression. Front Oncol. 2023;13:1224125.","journal-title":"Front Oncol"},{"key":"4812_CR167","doi-asserted-by":"crossref","unstructured":"Ikura H et al. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis. Int J Mol Sci, 2022. 23(11).","DOI":"10.3390\/ijms23116336"},{"key":"4812_CR168","doi-asserted-by":"crossref","unstructured":"Guo W et al. Identification and Characterization of Multiple Myeloma Stem Cell-Like Cells. Cancers (Basel), 2021. 13(14).","DOI":"10.3390\/cancers13143523"},{"issue":"15","key":"4812_CR169","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.18632\/oncotarget.27973","volume":"12","author":"A Thakurta","year":"2021","unstructured":"Thakurta A, et al. Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. Oncotarget. 2021;12(15):1555\u201363.","journal-title":"Oncotarget"},{"key":"4812_CR170","doi-asserted-by":"publisher","first-page":"926975","DOI":"10.3389\/fonc.2022.926975","volume":"12","author":"X Bao","year":"2022","unstructured":"Bao X, et al. Molecular Mechanism of \u03b2-Sitosterol and its Derivatives in Tumor Progression. Front Oncol. 2022;12:926975.","journal-title":"Front Oncol"},{"issue":"7","key":"4812_CR171","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2174\/1871520622666220831124321","volume":"23","author":"A Ullah","year":"2023","unstructured":"Ullah A, et al. Molecular Mechanisms of Sanguinarine in Cancer Prevention and Treatment. Anticancer Agents Med Chem. 2023;23(7):765\u201378.","journal-title":"Anticancer Agents Med Chem"},{"issue":"2","key":"4812_CR172","first-page":"131","volume":"142","author":"S Bird","year":"2023","unstructured":"Bird S, Pawlyn C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood. 2023;142(2):131\u201340.","journal-title":"Blood"},{"key":"4812_CR173","doi-asserted-by":"publisher","first-page":"13","DOI":"10.25259\/Cytojournal_64_2023","volume":"21","author":"J Zhang","year":"2024","unstructured":"Zhang J, Ding X, Ding X. Exploring the efficacy and safety of anti-BCMA chimeric antigen receptor T-cell therapy for multiple myeloma: Systematic review and meta-analysis. Cytojournal. 2024;21:13.","journal-title":"Cytojournal"},{"issue":"1","key":"4812_CR174","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13(1):117.","journal-title":"Blood Cancer J"},{"issue":"7","key":"4812_CR175","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3324\/haematol.2022.281628","volume":"108","author":"N Asherie","year":"2023","unstructured":"Asherie N, et al. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed\/refractory multiple myeloma: results from a phase I clinical trial. Haematologica. 2023;108(7):1827\u201339.","journal-title":"Haematologica"},{"issue":"4","key":"4812_CR176","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3324\/haematol.2020.266841","volume":"108","author":"X Zhou","year":"2023","unstructured":"Zhou X, et al. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2023;108(4):958\u201368.","journal-title":"Haematologica"},{"issue":"11","key":"4812_CR177","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00018-022-04551-4","volume":"79","author":"M Behroozaghdam","year":"2022","unstructured":"Behroozaghdam M, et al. Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action. Cell Mol Life Sci. 2022;79(11):539.","journal-title":"Cell Mol Life Sci"},{"key":"4812_CR178","doi-asserted-by":"crossref","unstructured":"Bartnik M et al. Evaluation of the Biological Effect of Non-UV-Activated Bergapten on Selected Human Tumor Cells and the Insight into the Molecular Mechanism of Its Action. Int J Mol Sci, 2023. 24(21).","DOI":"10.3390\/ijms242115555"},{"key":"4812_CR179","doi-asserted-by":"crossref","unstructured":"Ostapi\u0144ska K, Styka B, Lejman M. Insight into the Molecular Basis Underlying Chromothripsis. Int J Mol Sci, 2022. 23(6).","DOI":"10.3390\/ijms23063318"},{"issue":"10","key":"4812_CR180","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2174\/1386207323999201027225305","volume":"24","author":"F Alhmied","year":"2021","unstructured":"Alhmied F, et al. Molecular Mechanisms of Thymoquinone as Anticancer Agent. Comb Chem High Throughput Screen. 2021;24(10):1644\u201353.","journal-title":"Comb Chem High Throughput Screen"},{"key":"4812_CR181","doi-asserted-by":"publisher","first-page":"1291920","DOI":"10.3389\/fphar.2023.1291920","volume":"14","author":"Q Cao","year":"2023","unstructured":"Cao Q, et al. Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review. Front Pharmacol. 2023;14:1291920.","journal-title":"Front Pharmacol"},{"key":"4812_CR182","unstructured":"FDA Alerts Healthcare Professionals and Oncology Clinical investigators about two clinical trials. FDA, 2017."},{"issue":"7","key":"4812_CR183","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.3324\/haematol.2015.124164","volume":"100","author":"EM Ocio","year":"2015","unstructured":"Ocio EM, et al. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. Haematologica. 2015;100(7):e289\u201391.","journal-title":"Haematologica"},{"issue":"14","key":"4812_CR184","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","volume":"122","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122(14):2331\u20137.","journal-title":"Blood"},{"issue":"3","key":"4812_CR185","first-page":"300","volume":"148","author":"A Afrough","year":"2025","unstructured":"Afrough A, et al. Toxicity of CAR T-Cell Therapy for Multiple Myeloma. Acta Haematol. 2025;148(3):300\u201314.","journal-title":"Acta Haematol"},{"issue":"2","key":"4812_CR186","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32.","journal-title":"Blood Cancer J"},{"key":"4812_CR187","doi-asserted-by":"publisher","first-page":"678634","DOI":"10.3389\/fonc.2021.678634","volume":"11","author":"A Wahab","year":"2021","unstructured":"Wahab A, et al. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma. Front Oncol. 2021;11:678634.","journal-title":"Front Oncol"},{"issue":"11","key":"4812_CR188","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","volume":"8","author":"E Letouz\u00e9","year":"2024","unstructured":"Letouz\u00e9 E, et al. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024;8(11):2952\u20139.","journal-title":"Blood Adv"},{"key":"4812_CR189","doi-asserted-by":"publisher","first-page":"899272","DOI":"10.3389\/fonc.2022.899272","volume":"12","author":"J Schwestermann","year":"2022","unstructured":"Schwestermann J, et al. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. Front Oncol. 2022;12:899272.","journal-title":"Front Oncol"},{"issue":"10","key":"4812_CR190","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.2174\/1871520622666220519102948","volume":"23","author":"JB De Sanctis","year":"2023","unstructured":"De Sanctis JB, et al. Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy. Anticancer Agents Med Chem. 2023;23(10):1122\u201344.","journal-title":"Anticancer Agents Med Chem"},{"issue":"28","key":"4812_CR191","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.2174\/1381612827666210426100206","volume":"27","author":"A Salmaninejad","year":"2021","unstructured":"Salmaninejad A, et al. Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials. Curr Pharm Des. 2021;27(28):3161\u20139.","journal-title":"Curr Pharm Des"},{"key":"4812_CR192","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-biochem-090920-103246","volume":"91","author":"Y Gu","year":"2022","unstructured":"Gu Y, Desai A, Corbett KD. Evolutionary Dynamics and Molecular Mechanisms of HORMA Domain Protein Signaling. Annu Rev Biochem. 2022;91:541\u201369.","journal-title":"Annu Rev Biochem"},{"key":"4812_CR193","doi-asserted-by":"publisher","first-page":"1287505","DOI":"10.3389\/fphar.2023.1287505","volume":"14","author":"S Cotino-N\u00e1jera","year":"2023","unstructured":"Cotino-N\u00e1jera S, et al. Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer. Front Pharmacol. 2023;14:1287505.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4812_CR194","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier SM, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12(1):6960.","journal-title":"Nat Commun"},{"key":"4812_CR195","doi-asserted-by":"crossref","unstructured":"Michalkova R et al. Molecular Mechanisms of Antiproliferative Effects of Natural Chalcones. Cancers (Basel), 2021. 13(11).","DOI":"10.3390\/cancers13112730"},{"key":"4812_CR196","doi-asserted-by":"crossref","unstructured":"Barankiewicz J et al. CRL4(CRBN) E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma. Cancers (Basel), 2022. 14(18).","DOI":"10.3390\/cancers14184492"},{"key":"4812_CR197","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","volume":"9","author":"T Jelinek","year":"2018","unstructured":"Jelinek T, Paiva B, Hajek R. Update on PD-1\/PD-L1 Inhibitors in Multiple Myeloma. Front Immunol. 2018;9:2431.","journal-title":"Front Immunol"},{"issue":"1","key":"4812_CR198","first-page":"256","volume":"109","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma. Haematologica. 2024;109(1):256\u201371.","journal-title":"Haematologica"},{"key":"4812_CR199","doi-asserted-by":"crossref","unstructured":"Kciuk M et al. Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. Cancers (Basel), 2023. 15(10).","DOI":"10.3390\/cancers15102721"},{"key":"4812_CR200","doi-asserted-by":"crossref","unstructured":"Bakrim S et al. Dietary Phenolic Compounds as Anticancer Natural Drugs: Recent Update on Molecular Mechanisms and Clinical Trials. Foods, 2022. 11(21).","DOI":"10.3390\/foods11213323"},{"issue":"Pt 2","key":"4812_CR201","doi-asserted-by":"publisher","first-page":"108703","DOI":"10.1016\/j.compbiolchem.2025.108703","volume":"120","author":"B He","year":"2026","unstructured":"He B, et al. Microbiome-transcriptome-histology triad enhances survival risk stratification in multiple cancers. Comput Biol Chem. 2026;120(Pt 2):108703.","journal-title":"Comput Biol Chem"},{"key":"4812_CR202","doi-asserted-by":"publisher","first-page":"103950","DOI":"10.1016\/j.ebiom.2022.103950","volume":"78","author":"Z Yu","year":"2022","unstructured":"Yu Z, et al. Indirubin-3\u2019-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. EBioMedicine. 2022;78:103950.","journal-title":"EBioMedicine"},{"issue":"2","key":"4812_CR203","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/physiologia3020013","volume":"3","author":"S Banerjee","year":"2023","unstructured":"Banerjee S, Banerjee S. Anticancer Potential and Molecular Mechanisms of Cinnamaldehyde and Its Congeners Present in the Cinnamon Plant. Physiologia. 2023;3(2):173\u2013207.","journal-title":"Physiologia"},{"key":"4812_CR204","doi-asserted-by":"crossref","unstructured":"Matula Z et al. Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells. Cancers (Basel), 2021. 13(14).","DOI":"10.3390\/cancers13143461"},{"key":"4812_CR205","doi-asserted-by":"crossref","unstructured":"Pagano C et al. Molecular Mechanism of Cannabinoids in Cancer Progression. Int J Mol Sci, 2021. 22(7).","DOI":"10.3390\/ijms22073680"},{"issue":"1","key":"4812_CR206","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood.2025029950","volume":"147","author":"Z Yan","year":"2026","unstructured":"Yan Z, et al. Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma. Blood. 2026;147(1):48\u201360.","journal-title":"Blood"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04812-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04812-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04812-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:19:57Z","timestamp":1776831597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04812-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":206,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4812"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04812-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Generative AI tools (instatext, Wordvice, and DeepL) were used only to improve grammar, phrasing, and overall readability (language polishing and structural editing). No generative AI or large language model produced, verified, interpreted, or contributed substantive scientific content, data analysis, interpretations, conclusions, or clinical recommendations in this manuscript. All scientific content and final wording were created, reviewed, and approved by the named human authors, who take full responsibility for the content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"619"}}